modelTolvaptan_Lanke2019_base
Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | tolvaptan |
| ATC code: | C03XA01 |
| model: | one compartment, oral dosing (PK_1C_enteral) |
| source: | Lanke S et al. 2019 |
| population: | adults with autosomal dominant polycystic kidney disease |
| measured compound: | tolvaptan |
| review: | curated candidate |
| record page: | pharmacolibrary-docs |
Parameters as reported in the paper
| parameter | value | unit | meaning |
|---|---|---|---|
| CL/F (L/h) | 11.4 | L/h | CL/F |
| Vd/F (L) | 109 | L | V/F |
| D1 (h) | 0.55 | h | D1 |
| k a (h -1 ) | 1.34 | h -1 | kabs |
About tolvaptan
Tolvaptan is a vasopressin receptor antagonist used to treat low blood sodium (hyponatremia) linked to heart failure, cirrhosis, or inappropriate antidiuretic hormone secretion, and is also authorised for autosomal dominant polycystic kidney disease. It remains in use, with authorised products in the European Union, though it carries a boxed warning.
Summary written by glm-5.3-flash from Wikidata Q426132 and the WHO ATC classification and the EMA medicines list; not checked by a person.
Identity, molar mass and metabolites: Tolvaptan.
References
Lanke S et al. (2019). Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease. Journal of clinical pharmacology 59(5):763–770. DOI:10.1002/jcph.1370 PUBMED:30618157
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Real | Cl_ref | 3.1666666666666667e-06 | Cl [m3/s] |
| Real | Vd_ref | 0.109 | Vd [m3] |
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.0009 | Volume of distribution per kg (default 0.9 L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 1 | bioavailability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 2.7777777777777776e-7 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1e-4 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
| Info › Therapeutic range (metadata, not used in equations) | |||
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | maximal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Info › Substance metadata | |||
| Modelica.Units.SI.MolarMass | MM (from PK_1C) | 0 | molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0) |
| Info › Substance metadata (not used in equations) | |||
| Pharmacolibrary.Types.Dose | LD50 (from PK_1C) | 0 | median lethal dose [mg/kg]; 0 = unknown |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models) |
Revisions
- 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Lanke_2019: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: curated candidate